in vivo blog is no more.
deals of the week takes stock in m&a
what is the buoyant biotech ipo scene doing to private biotech m&a trends? fotf says: not much
stakeholders in consumer genomics, read this
dotw keeps tabs as tax trimming fuels deals
deals of the week: novartis places bid to dominate in cancer
financings of the fortnight and the neverending venture round
deals of the week: ucsf catalyzes r&d tech-transfer deals with private sector
can novel-novel combinations work? deals of the week watches merck test the waters
these days, you can't spell financings of the fortnight without "i-p-o"
deals of the week looks at the intersection of patient empowerment, generic drugs, and macaroni & cheese
deals of the week: new academia/industry partnership template in eisai/jhu collaboration?
financings of the fortnight asks for the envelope, please...
deals of the week: new remedies sought from nature and old technologies
return to seller: glycofi next tech to exit merck?
jpm survival guide: dotw keeps the party going
a rush and a push and the financings of the fortnight is ours
and the roger goes to ... our deals of the year winners!
2013 deals review finds spec pharma, bolt ons dominated m&a
three polls, one page: vote for ivbs deals of the year